

Mattia Zampieri

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2940869/publications.pdf>

Version: 2024-02-01

20
papers

241
citations

932766

10
h-index

1058022

14
g-index

20
all docs

20
docs citations

20
times ranked

168
citing authors

#	ARTICLE	IF	CITATIONS
1	Incidence and risk factors for pacemaker implantation in light-chain and transthyretin cardiac amyloidosis. <i>European Journal of Heart Failure</i> , 2022, 24, 1227-1236.	2.9	28
2	Changes in the perceived epidemiology of amyloidosis: 20 year-experience from a Tertiary Referral Centre in Tuscany. <i>International Journal of Cardiology</i> , 2021, 335, 123-127.	0.8	21
3	Pathophysiology and Treatment of Hypertrophic Cardiomyopathy: New Perspectives. <i>Current Heart Failure Reports</i> , 2021, 18, 169-179.	1.3	19
4	Emerging Medical Treatment for Hypertrophic Cardiomyopathy. <i>Journal of Clinical Medicine</i> , 2021, 10, 951.	1.0	18
5	Current patterns of beta-blocker prescription in cardiac amyloidosis: an Italian nationwide survey. <i>ESC Heart Failure</i> , 2021, 8, 3369-3374.	1.4	18
6	Mavacamten, a Novel Therapeutic Strategy for Obstructive Hypertrophic Cardiomyopathy. <i>Current Cardiology Reports</i> , 2021, 23, 79.	1.3	17
7	Quality of life assessment in amyloid transthyretin (ATTR) amyloidosis. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13598.	1.7	16
8	Prevalence, causes and predictors of cardiovascular hospitalization in patients with hypertrophic cardiomyopathy. <i>International Journal of Cardiology</i> , 2020, 318, 94-100.	0.8	15
9	Cardiac involvement in eosinophilic granulomatosis with polyangiitis (formerly Churg-Strauss) Tj ETQq1 1 0.784314 rgBT /Overlock 100. <i>Journal of Internal Medicine</i> , 2021, 85, 68-79.	1.0	14
10	Targeted Medical Therapies for Hypertrophic Cardiomyopathy. <i>Current Cardiology Reports</i> , 2020, 22, 10.	1.3	12
11	Sex-related differences in clinical presentation and all-cause mortality in patients with cardiac transthyretin amyloidosis and light chain amyloidosis. <i>International Journal of Cardiology</i> , 2022, 351, 71-77.	0.8	11
12	Early Diagnosis and Outcome in Patients With Wild-Type Transthyretin Cardiac Amyloidosis. <i>Mayo Clinic Proceedings</i> , 2021, 96, 2185-2191.	1.4	10
13	Incidence of light chain amyloidosis in Florence metropolitan area, Italy: a population-based study. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2021, 28, 211-212.	1.4	9
14	Racial Differences in Val122Ile-Associated Transthyretin Cardiac Amyloidosis. <i>Journal of Cardiac Failure</i> , 2022, 28, 950-959.	0.7	8
15	SGLT2i in patients with transthyretin cardiac amyloidosis, a well-tolerated option for heart failure treatment? Results from a small, real-world, patients series. <i>Internal and Emergency Medicine</i> , 2022, 17, 1243-1245.	1.0	7
16	Circulating biomarkers in diagnosis and management of cardiac amyloidosis: a review for internist. <i>Internal and Emergency Medicine</i> , 2022, 17, 957-969.	1.0	6
17	Cardiac magnetic resonance in patients with ARVC and family members: the potential role of native T1 mapping. <i>International Journal of Cardiovascular Imaging</i> , 2021, 37, 2037-2047.	0.7	5
18	Ventricular tachyarrhythmias and sudden cardiac death in light-chain amyloidosis: a clash of cardio-toxicities?. <i>British Journal of Haematology</i> , 2021, 193, e27-e31.	1.2	5

#	ARTICLE	IF	CITATIONS
19	Prevalence and clinical correlates of exercise-induced ventricular arrhythmias in arrhythmogenic right ventricular cardiomyopathy. International Journal of Cardiovascular Imaging, 2021, , 1.	0.7	1
20	Prevalence and prognostic significance of RV uptake (biventricular uptake) at planar scintigraphy in patients with ATTR cardiac amyloidosis. European Heart Journal Supplements, 2021, 23, .	0.0	1